Agreement with Texas Biomed for Galidesivir Program
Filed with ASX · · 3 pages · English
MELBOURNE Australia, 17 December 2025: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to advise it has secured a Master Service Agreement (‘MSA’) with Texas Biomedical Research Institute (‘Texas Biomed’), a leading biosafety level 4 (‘BSL-4’) facility in the USA. Texas Biomed is one of four BSL-4 facilities in the US that can
Island Pharmaceuticals Ltd on 6ix
Story so far
Earlier from Island Pharmaceuticals
- Island expands Galidesivir IP with US Patent Grant
- Additional FDA Submission completed for Galidesivir
- Options exercised raises $1million
- Coalition acceptance to advance US procurement & stockpiling
- Island engages advisers to advance biodefence strategy
Later from Island Pharmaceuticals
- Ongoing engagement with the US FDA
- US Patent Granted for Galidesivir in filoviridae viruses
- Quarterly Appendix 4C and Activities Report
- FDA confirms Galidesivir approval pathway
- $9m placement to advance US biodefence opportunity
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals